Drugs / MP0317
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05098405 | Oct 2021 → Jan 2024 | cancer | Molecular Partners AG | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07036380 | Dec 2025 → Nov 2028 expected | biliary tract cancer | Centre Hospitalier Universitaire de Besancon | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MP0317 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07036380 ↗ |
| Action | Activate | “α-FAPxCD40 activation of CD40 depends on binding to fibroblast activation protein (FAP)” PMID 35319751 ↗ May 2022 |
| Modality | Protein / enzyme biologic | “MP0317 (FAP x CD40 DARPin)” PMID 42067655 ↗ May 2026 |
| Route | Intravenous | “Study treatment will be administered as an intravenous (IV) infusion” NCT05098405 ↗ |
| Target | CD40 | “a DARPin® drug candidate targeting fibroblast activation protein (FAP) and CD40.” NCT05098405 ↗ |
| Target | FAP | “a DARPin® drug candidate targeting fibroblast activation protein (FAP) and CD40.” NCT05098405 ↗ |